ARDS vs. SCPS, EVLO, CMRA, GNCAQ, GNCA, STAB, AMPE, EFTR, HSTO, and ONCSQ
Should you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), eFFECTOR Therapeutics (EFTR), Histogen (HSTO), and OncoSec Medical (ONCSQ). These companies are all part of the "pharmaceutical products" industry.
Aridis Pharmaceuticals vs. Its Competitors
Aridis Pharmaceuticals (NASDAQ:ARDS) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.
9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Aridis Pharmaceuticals has a beta of 11.59, indicating that its stock price is 1,059% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500.
In the previous week, Aridis Pharmaceuticals had 1 more articles in the media than Scopus BioPharma. MarketBeat recorded 1 mentions for Aridis Pharmaceuticals and 0 mentions for Scopus BioPharma. Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.
Summary
Aridis Pharmaceuticals beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.
Get Aridis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ARDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aridis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ARDS) was last updated on 7/16/2025 by MarketBeat.com Staff
